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Like many sarcomas, synovial sarcoma is driven by a characteristic oncogenic transcription factor fusion,
SS18-SSX. In this issue of Cancer Cell, Su et al. elucidate the protein partners necessary for target gene
misregulation and demonstrate a direct effect of histone deacetylase inhibitors on the SS18-SSX complex
composition, expression misregulation, and apoptosis.It has been more than 25 years since the
recurrent translocation between chromo-
somes 18 and X in synovial sarcoma
(SS) was first reported (Limon et al.,
1986) and 18 years since the cloning of
the productive fusion between SYT/
SS18 on chromosome 18 and SSX on
chromosome X generated by this translo-
cation (Clark et al., 1994). Although there
have been great advancements in under-
standing the basic biology of this
rare cancer, therapeutic strategies and
clinical outcomes have remained largely
unchanged since the 1980s, and large
tumors, metastatic disease, and relapse
are frequently impossible to control. In
a new study, Su et al. (2012 [in this issue
of Cancer Cell]) not only provide deep
insight into the molecular mechanisms
at work in SS but also suggest an unex-
pected explanation for the sensitivity of
SS to histone deacetylase (HDAC) inhibi-
tion in preclinical models. Beyond helping
to guide current clinical trials of HDAC
inhibitors in SS, this study has implica-
tions for other transcription factor-fusion
driven malignancies.
Sarcomas are a heterogeneous group
of tumors of mesenchymal origin.
Although representing less than 1% of
adult neoplasms, they account for
15% of all pediatric malignancies. As in
leukemia and lymphoma, chromosome
translocations that create oncogenic
fusion proteins are common in sarcomas
and are often pathognomonic for the
particular sarcoma type (Davis and Melt-
zer, 2007). Interestingly, a large number
of these fusion proteins involve transcrip-
tion factors, and the misregulation of
target gene expression is a clear driving
mechanism of malignancy. SS contains
fusions of the transcriptional coactivatorSYT/SS18 with the SSX family of tran-
scriptional corepressors (most frequently
SSX1 or SSX2). The fusion protein typi-
cally contains nearly the entirety of SS18
and the C-terminal domains of SSX,
which contain the strongest repressive
activities (de Bruijn et al., 2007). Although
the typical location near the synovial joints
of the limbs gave rise to its name, SS
occurs in many other sites, and in fact
most likely originates in a myogenic
progenitor compartment rather than
synovial tissue (Haldar et al., 2007). SS
are classified histologically as monopha-
sic SS, in which all tumor cells exhibit
a spindle cell morphology; biphasic SS,
which contains a mixture of spindle
cells and cells showing epithelial dif-
ferentiation; and more rarely, poorly
differentiated SS.
Su et al. (2012) began by identifying in-
teractors of the endogenous SS18-SSX
fusion protein in an SS cell line and imme-
diately made two very important discov-
eries. The first reveals how SS18-SSX is
recruited to specific genomic locations,
an important unresolved question in the
field because the fusion protein lacks
direct DNA binding domains. Of interest,
one interactor identified was the se-
quence specific transcriptional activator
activating transcription factor 2 (ATF2).
In follow-up experiments, the authors
established that, at least for a set of
important target genes, SS18-SSX is
recruited directly to promoters by ATF2.
The second important discovery was the
interaction of SS18-SSX with the tran-
scriptional corepressor transducin-like
enhancer of split 1 (TLE1). High levels
of TLE family members, especially TLE1,
have been identified as potential bio-
markers for SS (Terry et al., 2007), butCancer Cell 2their functional role in the disease has
been unclear. The authors demonstrate
that TLE1 serves as a bridge for tethering
transcriptional repressors such asHDAC1
and PRC2 to SS18-SSX. Furthermore,
the authors demonstrate for several
genes normally activated by ATF2 that
SS18-SSX recruits dominant repressive
activities mediated by TLE1/HDAC1 and
PRC2. Thus, an elegant model is devel-
oped to explain the effects of the SS18-
SSX: targeting to DNA through the
interaction of the SS18 moiety with the
transcriptional activator ATF2 and recruit-
ment of the repressive HDAC and PRC2
to ATF2 targets through the SSX portion
of the fusion protein. At least for certain
target genes, the repressive activities
dominate, and aberrant gene repression
contributes to the tumor phenotype.
Consistent with this model, disruption
of the complex by RNAi depletion of
its components leads to target gene
derepression and increased apoptosis.
Perhaps most intriguing and of immediate
therapeutic relevance is the discovery
that HDAC inhibitor treatment disrupts
the interaction between TLE1 and the
fusion protein, thus releasing the HDAC
and PRC2 complexes from ATF2 target
promoters and derepressing target gene
expression. While the mechanism could
certainly be indirect, one possibility would
be that either TLE1 or SS18-SSX is itself
acetylated, thereby destabilizing the
interaction. HDAC inhibitors are of sig-
nificant clinical interest, with vorinostat
and romidepsin now FDA-approved for
treatment of cutaneous T cell lymphoma.
Since they appear to target a core mech-
anism of SS, it is certainly plausible that
this class of drugs will provide significant
benefits to patients.1, March 20, 2012 ª2012 Elsevier Inc. 323
Cancer Cell
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lishes these molecular mechanisms of
the oncogenic fusion protein and the
target genes investigated are certainly
interesting ones, there is as yet no cohe-
sive explanation of how normal progenitor
cells are transformed by SS18-SSX.
Which pathways are affected? Is it purely
aberrant repression of pathways such as
differentiation, cell death, and/or senes-
cence that drive the disease? The glan-
dular structures apparent in the biphasic
subtype of SS suggest that the tumor is
not characterized by a simple block of
normal mesenchymal differentiation but
raises the possibility that the cells are
being driven into an aberrant state. A
deeper dissection of the transcriptional
networks misregulated by SSX18-SSX
will be necessary tomore fully understand
the functional consequences of SSX18-
SSX activity.
It is worth noting the relevance of these
discoveries to other malignancies. Onco-
genic fusions involving transcription
factors is a common theme in malignan-
cies of mesenechymal and hematopoetic
lineages as well as in certain epithelial
tumors such as prostate cancer. ATF,
TLE, Polycomb, and HDAC family mem-
bers have all been implicated in a wide
array of cancer types through altered
expression levels as well as somatic
mutations. Perhaps most relevant to the
SS results, endometrial stromal sarcoma
(ESS) is often driven by fusions of the
zinc finger transcription factor JAZF1
with Polycomb proteins SUZ12 or PHF1,324 Cancer Cell 21, March 20, 2012 ª2012 Eor fusion of PHF1 and EPC1 (Chiang
et al., 2011). Presumably, this leads to
mislocalization of Polycomb complexes
on the chromatin and misregulation of
target genes. ESS has also been shown
to be sensitive to HDAC inhibitors (Hrzen-
jak et al., 2008). While acute promyeloctic
leukemia (APL) and SS are quite different
diseases, the PML-retinoic acid receptor
alpha (RARa) fusion which defines APL
also functions largely through patholog-
ical recruitment of HDACs and PRC2
(Villa et al., 2007). In normal physiology
the RARa switches between repressing
target gene expression when retinoic
acid (RA) levels are low and the receptor
is unliganded and activating target gene
expression when RA levels are high
and bind the receptor. The oncogenic
mechanism of the PML-RARa fusion is
persistent association with corepressors
regardless of physiological RA concen-
trations. The standard and typically
successful treatment for APL is all-trans
retinoic acid, which leads to release of
corepressors from PML-RARa, derepres-
sion of target genes, terminal differentia-
tion, and apoptosis.
The study of Su et al. (2012) is a sig-
nificant addition to our understanding
of the basic biological mechanisms of
SS and highlights the commonly under-
appreciated role of transcriptional repres-
sion by oncogenic transcription factor-
fusions. The phase I and II clinical trials
for HDAC inhibitors in sarcoma currently
underway, the outcomes of which are
much anticipated, now have a strongerlsevier Inc.biological rationale and context for inter-
pretation of their results. Most intriguingly,
the effects of HDAC inhibitors on
multiprotein complex composition and
possibly on non-histone targets are likely
to be of more general importance in
numerous systems.
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